Here’s Why Eli Lilly & Co. Stock Gapped Lower

Eli Lilly & Co. (LLY) just plummeted to $134 and could be headed to $130 near-term.  All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvement. “The study of the monoclonal antibody called bamlanivimab was initially paused by the company on … Continue reading “Here’s Why Eli Lilly & Co. Stock Gapped Lower”